Perrigo Company plc

PRGO

IE00BGH1M568

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 15:41:45 2024-07-16 EDT			5-day change	1st Jan Change
27 ^USD	+0.35%		+2.08%	-15.97%

07-11	Piper Sandler Trims Price Target on Perrigo to $35 From $36, Maintains Overweight Rating	MT
07-10	Perrigo Divests HRA Pharma Rare Diseases Business to Esteve Healthcare	MT

Perrigo Names James Dillard as Chief Scientific Officer

January 14, 2019 at 09:53 am

Perrigo announced that it has named James Dillard as chief scientific officer. Dillard is joining Perrigo from Altria Group, where he served as chief innovation officer.

Latest news about Perrigo Company plc

Piper Sandler Trims Price Target on Perrigo to $35 From $36, Maintains Overweight Rating	07-11	MT
Perrigo Divests HRA Pharma Rare Diseases Business to Esteve Healthcare	07-10	MT
Esteve Healthcare S.L. completed the acquisition of HRA Pharma Rare Diseases America, LLC from Perrigo Company plc.	07-09	CI
Piper Sandler Adjusts Price Target on Perrigo to $36 From $39, Maintains Overweight Rating	06-13	MT
Transcript : Perrigo Company plc Presents at Oppenheimer's 24th Annual Virtual Consumer Growth and E-Commerce Conference, Jun-11-2024 01:30 PM	06-11
Perrigo Company plc Appoints Todd Penegor as Member of Board and to Serve on Audit Committee, Effective June 21, 2024	06-10	CI
Perrigo Company plc Announces Executive Changes	05-28	CI
Perrigo's Q1 Adjusted Earnings, Net Sales Drop	05-07	MT
Transcript : Perrigo Company plc, Q1 2024 Earnings Call, May 07, 2024	05-07
Earnings Flash (PRGO) PERRIGO COMPANY Posts Q1 Revenue $1.08B	05-07	MT
Earnings Flash (PRGO) PERRIGO COMPANY Posts Q1 EPS $0.29, vs. Street Est of $0.23	05-07	MT
Perrigo Company plc Reports Earnings Results for the First Quarter Ended March 30, 2024	05-07	CI
Perrigo Company plc Reaffirms Earnings Guidance Year 2024 and Provides Sales Guidance for the Second Half of 2024	05-07	CI
Perrigo Announces Executive Transition for Its Consumer Self-Care International Business	05-07	CI
Perrigo Keeps Quarterly Dividend at $0.276 Per Share; Payable June 18 to Shareholders on May 31	05-01	MT
Perrigo Company plc Announces Quarterly Dividend, Payable on June 18, 2024	05-01	CI
Sector Update: Health Care Stocks Decline Late Afternoon	04-25	MT
Perrigo Receives Binding Offer to Sell HRA Pharma Rare Diseases Business for Up to $295 Million	04-25	MT
Esteve Healthcare S.L. entered into a Purchase and Sale Agreement to acquire HRA Pharma Rare Diseases America, LLC from Perrigo Company plc for approximately ?280 million.	04-24	CI
Piper Sandler Raises Perrigo's Price Target to $39 From $35, Maintains Overweight Rating	04-08	MT
CVS Caremark to cover Perrigo's birth control pill in US at zero cost for plan sponsors	04-04	RE
Multiple CVS Caremark Plans to Cover Perrigo's Opill at No Cost	04-04	MT
Multiple CVS Caremark Plans Reportedly to Cover Perrigo's Opill at No Cost	04-04	MT
Sector Update: Health Care Stocks Rise Late Afternoon	03-19	MT
Sector Update: Health Care Stocks Higher in Tuesday Afternoon Trading	03-19	MT

Perrigo Company plc is a provider of over the counter (OTC) health and wellness solutions that are designed to enhance individual well-being. Its segments include Consumer Self-Care Americas (CSCA) and Consumer Self-Care International (CSCI). The CSCA segment comprises of its consumer self-care business in the United States and Canada. It primarily provides its customers self-care products that are sold and marketed under the customer's own brands and/or exclusive brands. The CSCI segment comprises of its consumer self-care business outside of the United States and Canada, primarily in Europe and Australia. These products are developed, manufactured, marketed, and distributed by the Company. Its product categories include Upper Respiratory, Pain and Sleep-Aids, Skincare and Personal Hygiene, Digestive Health, and Nutrition. Its primary branded products are sold under brand names Compeed, Dr. Fresh, Firefly, Good Sense, Mederma, Nasonex, Solpadeine, Coldrex, and Physiomer, among others.

Sector

Pharmaceuticals

Calendar

2024-08-06 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Perrigo Company plc

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

26.9 USD

Average target price

38.5 USD

Spread / Average Target

+43.12%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
PERRIGO COMPANY PLC	-15.97%	3.67B
ELI LILLY AND COMPANY	+61.17%	856B
NOVO NORDISK A/S	+38.95%	631B
JOHNSON & JOHNSON	-3.83%	359B
MERCK & CO., INC.	+15.36%	325B
ABBVIE INC.	+9.02%	297B
ROCHE HOLDING AG	+5.89%	234B
NOVARTIS AG	+16.53%	226B
AMGEN INC.	+15.81%	177B
PFIZER, INC.	+2.21%	165B

Other Pharmaceuticals

Perrigo Company plc

Equities

PRGO

IE00BGH1M568

Pharmaceuticals

Perrigo Names James Dillard as Chief Scientific Officer

Latest news about Perrigo Company plc

Chart Perrigo Company plc

Company Profile

Income Statement Evolution

Ratings for Perrigo Company plc

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals